Annals of Hematology

, Volume 86, Issue 7, pp 519–526 | Cite as

Suboptimal doses of low molecular weight heparin and acute venous thromboembolism. Data from the RIETE registry

  • Ma. Jesús Bruscas
  • José Antonio Nieto
  • Monserrat Perez-Pinar
  • Luciano López-Jiménez
  • Carmen Fernández-Capitán
  • Francisca López-Chuliá
  • Ma. Teresa Orue-Lecue
  • for the RIETE Investigators
Original Article

Abstract

The objective was to assess the use of suboptimal doses (60–149 UI kg−1 day−1) of low molecular weight heparin (LMWH) in the treatment of acute venous thromboembolism (VTE) in actual clinical practice and to evaluate the outcomes compared to standard doses (≥150 UI kg−1 day−1). Retrospective analysis of data from a multicenter registry of patients with VTE (RIETE; Registro Informatizado de Enfermedad TromboEmbólica). Patient characteristics, antithrombotic treatments, and 3-month outcomes were analyzed. We studied 12,302 patients with VTE; 10,524 patients were treated initially only with LMWH; 1,547 patients received suboptimal LMWH (mean = 122 UI kg−1 day−1), and 8,977 patients received full-dose LMWH (mean = 191 UI kg−1 day−1). The suboptimal group included significantly more patients with recent major bleeding, weight more than 100 kg, raised creatinine, or deep vein thrombosis. No significant differences in mortality rate (7.7 vs 7.8%), VTE recurrence (2.7 vs 2.3%), or fatal hemorrhage (0.6 vs 0.6%) occurred between the suboptimal and the standard group. Major bleeding episodes occurred more frequently in the patients with pulmonary embolism treated with suboptimal LMWH (4.5 vs 2.4%; p = 0.02). In the multivariate analysis, after adjusting for bleeding risk factors, major hemorrhage was not associated with the heparin dose. Suboptimal doses of LMWH are used in actual clinical practice in a reduced group of patients at an outcome rate not very different to that of standard doses. Bleeding episodes depend more on the patient’s characteristics than on the LMWH dose. Randomized trials should be performed to corroborate these results.

Keywords

Venous thromboembolism Low molecular weight heparin Suboptimal dose Hemorrhage Outcome 

Notes

Acknowledgments

We express our gratitude to Sanofi-Aventis for supporting this registry with an unrestricted educational grant and the Registry Coordinating Center, S & H Medical Science Service, for their logistic and administrative support. We thank Ms. Uta M. Klepzig for the assistance in the preparation of the manuscript. The project has been partially supported by Red Respira from the Instituto Carlos III (RedRespira-ISCiii-RTIC-03/11).

Conflict of interest statement

None was declared.

References

  1. 1.
    Büller HR, Agnelli G, Hull RD, Hyers TH, Prins MH, Raskob GE (2004) Antithrombotic therapy for venous thromboembolic disease. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126: 401S–428SPubMedCrossRefGoogle Scholar
  2. 2.
    Hirsh J, Raschke R (2004) Heparin and low-molecular-weight heparin. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:188S–203SPubMedCrossRefGoogle Scholar
  3. 3.
    Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM (1988) The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 28:609–618PubMedGoogle Scholar
  4. 4.
    Matzsch T, Bergqvist D, Hedner OR, Ostergaard P (1987) Effects of an enzymatically depolymerised heparin ace compared with conventional heparin in healthy volunteers. Thromb Haemost 57:97–101PubMedGoogle Scholar
  5. 5.
    Quinlan DJ, McQuillan TO, Eikelboom JW (2004) Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a goal-analysis of randomized controlled trials. Ann Intern Med 140:175–183PubMedGoogle Scholar
  6. 6.
    Bratt G, Tornebohm AND, Widlund L, Lockner D (1986) Low molecular weight heparine (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 42:613–620PubMedCrossRefGoogle Scholar
  7. 7.
    Brophy DF, Martin EJ, Best AM, Gehr TW, Carr ME (2004) Antifactor Xa activity correlates to thrombin generation cheats, platelet contactile forced and clot elastic modulus following former alive enoxaparin exposure in patients with and without renal dysfunction. Thromb Haemost 2:1299–1304CrossRefGoogle Scholar
  8. 8.
    Bianchini P, Bergonzini GL, Parma B, Osima B (1995) Relationship between captures antifactor Xa activity and the antithrombotic activity of heparins of molecular different mass. Haemostasis 25:288–298PubMedGoogle Scholar
  9. 9.
    Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, Owings JT (2004) Variability of captures anti-Xa activities with different lots of enoxaparin. Ann Pharmacother 38:563–568PubMedCrossRefGoogle Scholar
  10. 10.
    Greaves M (2002) Limitations of the laboratory monitoring of heparin therapy. Thromb Haemost 87:163–164PubMedGoogle Scholar
  11. 11.
    González-Fajardo JA, Arreba AND, Castrodeza J, Pérez JL, Fernández L, Agundez I, Mateo AM, Career S, Gutiérrez V, Cowboy C (1999) Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 30:283–292PubMedCrossRefGoogle Scholar
  12. 12.
    Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, Tagliaferri TO, Dettori AG (1994) Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 72:191–197PubMedGoogle Scholar
  13. 13.
    Marchetti M, Pistorio TO, Barone M, Serafini S, Barosi G (2001) Low-molecular-weight Heparin versus warfarin for secondary prophylaxis of venous thromboembolism. A cost-effectiviness analysis. Am J Med 111:159–160CrossRefGoogle Scholar
  14. 14.
    Veiga F, Scribe TO, Maluenda MP, López Rubio M, Margalet I, Lezana TO, Galician J, Riverside JM (2000) Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost 84:559–564PubMedGoogle Scholar
  15. 15.
    Arcelus JL, Monreal M, Caprini JA, Suarez C, González-Fajardo JA, for the RIETE investigators (2003) The management and outcome of acute venous thromboembolism: a prospective registry including 4,011 patients. J Vasc Surg 38:916–922PubMedCrossRefGoogle Scholar
  16. 16.
    Monreal M, Súarez C, González-Fajardo JA, Barba R, Uresandi F, Valle R, Rondón P, and the RIETE Investigators (2004) Management of patients with acute venous thromboembolism: findings from the RIETE Registry. Pathophysiol Haemost Thromb 33:330–334CrossRefGoogle Scholar
  17. 17.
    Nieto JA, Diaz de Tuesta A, Marchena J, Tiberio G, Todoli JA, Samperiz AL y Monreal M (2005) Clinical outcome of patients with venous thromboembolism and recent major bleeding: findings from a prospective registry (RIETE). J Thromb Haemost 3:703–709PubMedCrossRefGoogle Scholar
  18. 18.
    Monreal M, Kakkar AK, Caprini JA, Barba R, Uresandi F, Valle R, Suárez C, Otero R, the RIETE Investigators (2004) The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE Registry. J Thromb Haemost 2:1–7CrossRefGoogle Scholar
  19. 19.
    Wicki J, Perrier A, Perneger TV, Bounameaux H, Junod AF (2000) Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 84:548–552PubMedGoogle Scholar
  20. 20.
    Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O’Fallon WM, Melton LJ (2001) The epidemiology of venous thromboembolism in the community. Thromb Haemost 86:452–463PubMedGoogle Scholar
  21. 21.
    Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolani B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484–3488PubMedCrossRefGoogle Scholar
  22. 22.
    Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS (2000) Clinical risks factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 160:3431–3436PubMedCrossRefGoogle Scholar
  23. 23.
    Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S (2004) The risk of recurrent venous thromboembolism in men and women. N Engl J Med 350:2558–2563PubMedCrossRefGoogle Scholar
  24. 24.
    Jimenez D, Diaz G, Marin E, Vidal R, Sueiro A, Yusen RD (2006) The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism. Thromb Haemost 95:562–566PubMedGoogle Scholar
  25. 25.
    Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, HUet Y, Simonneau G (1998) A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 338:409–415PubMedCrossRefGoogle Scholar
  26. 26.
    Hansson PO, Sorbo J, Eriksson H (2000) Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 160:769–774PubMedCrossRefGoogle Scholar
  27. 27.
    Santamaría MG, Agnelli G, Taliani MR, Prandoni P, Moia M, Bazzan M, Guazzaloca G, Agneno W, Bertoldi A, Silingardi M, Tomasi C, Ambrosio GB (2005) Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Thromb Res 116:301–306PubMedCrossRefGoogle Scholar
  28. 28.
    Wells PS, Forgie MA, Simms M, Greene A, Touchie D, Lewis G, Anderson J, Rodger MA (2003) The outpatient bleeding risk index. Validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 163:917–920PubMedCrossRefGoogle Scholar
  29. 29.
    White RH, Beyth RJ, Zhou H, Romano PS (1999) Major bleeding after hospitalization for deep vein thrombosis. Am J Med 107:414–424PubMedCrossRefGoogle Scholar
  30. 30.
    Kuijer PMM, Hutten BA, Prins MH, Büller HR (1999) Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 159:457–460PubMedCrossRefGoogle Scholar
  31. 31.
    Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L (1987) Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 82:703–713PubMedCrossRefGoogle Scholar
  32. 32.
    Hull R, Raskob GE, Rosemblom D, Panju AA, Brill-Edwards P, Ginsberg JS, Hirsh J, Martín GJ, Green D (1990) Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 322:1260–1264PubMedCrossRefGoogle Scholar
  33. 33.
    Eriksson H, Lundstrom T, Wahlander K, Clason SB, Schulman S, THRIVE III Investigators (2005) Prognostic factors for recurrence of venous thromboembolism or bleeding during long term secondary prevention of VTE with ximelagatran. Thromb Haemost 94:522–527PubMedGoogle Scholar
  34. 34.
    Hull RD, Raskob GE, Rosemblom D, Lemaire J, Pineo GF, Baylis B, Ginsberg JS, Panju AA, Brill-Edwards P, Brant R (1992) Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 152:1589–1595PubMedCrossRefGoogle Scholar
  35. 35.
    Siegbahn A, Y-Hassan S, Boberg J, Bylund H, Neerstrand HS, Ostergaard P, Hedner U (1989) Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo. Thromb Res 55:767–768PubMedCrossRefGoogle Scholar
  36. 36.
    Bratt G, Tornebohm E, Widlund L, Lockner D (1986) Low molecular heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 42:613–620PubMedCrossRefGoogle Scholar
  37. 37.
    Samama MM, Gerotziafas GT (2000) Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 26:31–38PubMedCrossRefGoogle Scholar
  38. 38.
    Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS (1996) Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 100:269–277PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Ma. Jesús Bruscas
    • 1
  • José Antonio Nieto
    • 1
  • Monserrat Perez-Pinar
    • 1
  • Luciano López-Jiménez
    • 2
  • Carmen Fernández-Capitán
    • 3
  • Francisca López-Chuliá
    • 4
  • Ma. Teresa Orue-Lecue
    • 5
  • for the RIETE Investigators
  1. 1.Servicio de Medicina InternaHospital Virgen de la LuzCuencaSpain
  2. 2.Internal MedicineHospital Provincial Reina SofíaCordovaSpain
  3. 3.Internal MedicineHospital Universitario La PazMadridSpain
  4. 4.HematologyHospital Arnau de VilanovaValenciaSpain
  5. 5.HematologyHospital de NavarraNavarraSpain

Personalised recommendations